Senzime – Six Years of Compression, One Decision Point AheadSenzime ABOMXSTO_DLY:SEZITrueessence31Senzime is not a confirmed breakout stock yet, but the setup is getting harder to ignore and with an amazing risk reward based on of course profit but the technical, historical and fundamental conditions are very good. After years of drifting, the company has finally started to show real traction: a growing installed base, recurring sensor revenue, improving margins and a stated path toward profitability in 2026. It is still a small-cap medtech name and quarterly numbers can move around, but for once the fundamentals are no longer fighting the chart. What makes the case interesting now is not one single thing. It is the combination of several things lining up at roughly the same time: six years of compression, a tightening monthly structure, a weekly trigger getting close, and a period where the company has actually delivered several meaningful releases instead of just talking about potential. The backdrop has improved. In a fairly short period, Senzime launched the new TetraSens sensor, announced a pediatric hospital contract in the US, and introduced the TetraAnalytics cloud platform. For a company of this size, that matters. It is more execution density than the company has usually shown in earlier phases. Monthly structure – the big picture On the monthly chart, Senzime is approaching a rare higher-timeframe alignment where all moving averages I use (EMA 5, 9, 20 SMA50)are aligning just above the price on monthly under compression. This is not a normal short-term crossover. It is the kind of setup that only starts to appear after years of pressure, failed rallies and compression. The long-term downtrend from the 2020 high and the shorter multi-year trendline have now narrowed into the same decision zone. In other words, the chart is running out of room. The stock does not need to explode tomorrow, but it is getting close to a point where it probably cannot stay neutral much longer. Weekly structure The weekly chart holds the actual decisons. The first real trigger is still the weekly EMA 5/9 crossover. Without it, this is still just a watchlist setup. With it – and preferably with volume following – the structure opens up a lot faster. This is also where timing becomes interesting. Senzime has shown a fairly clear rhythm in recent years: Q1 tends to be quieter, May and June often turn into digestion, and July is where the stronger move has tended to come. In previous years, that seasonal window has produced moves ranging roughly from 40% to 140%, depending on where the stock entered the period and how strong the broader setup was. That does not mean it has to happen again, but it does show that when Senzime starts moving in this part of the calendar, the upside can become meaningful very quickly. Key levels • Invalidation: 4.10 • Accumulation / trigger zone: 4.60–5.00 • key : 5.00 • Breakout level 1: 5.40 – break of the 6-year trendline • Breakout level 2: 5.80 – break of the 4-year trendline Upside zones if the structure opens up: • 6.5 –7.5 – monthly SMA50 zone • 9.0 • 15.0 Above 5.50-6.00 – the chart starts to look very different. That is where the stock begins to move out of a six-year cage, and where the asymmetry becomes more interesting because there is relatively little historical congestion before the monthly SMA50 zone. Catalysts • Euroanaesthesia • Potential weekly EMA 5/9 crossover into late June / early July • Q2 report on July 16 • TetraSens US launch in Q3 • Profitability target by year-end The core of the case This is not a “buy because it is cheap” setup. It is a structural compression case with a very specific trigger. • Monthly tightening / alignment = the big-picture shift • Weekly EMA 5/9 crossover = the ignition • 5.50 - 6.00 = the levels where the structure really starts to open up Below that, this is still mostly a compression story. Above that, it can become something else: a stock moving out of a six-year base with room to reprice far beyond a normal micro-cap bounce.